drugset / Trial / NCT06388616
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of balcinrenone in patients with mild and moderate hepatic impairment in comparison to a matched healthy control group.
Timeline
- Start
- 2024-05-02
- Primary completion
- 2024-09-05
- Completion
- 2024-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | balcinrenone | Small molecule | 50 mg | Oral |
Indications
No indication recorded.